Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week open-label extension of lurasidone in bipolar I depression
2008-007483-42Phase 3Completed
- Sponsor
- Sunovion
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lurasidone in bipolar I disorder, sponsored by Sunovion. Primary endpoint: Long-term safety and tolerability. Started Jul 2009; status: completed.
02
Drugs
lurasidone
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on 2008-007483-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007483-42.